Efficacy and safety of olverembatinib in adult <scp>BCR</scp> :: <scp>ABL1</scp> ‐positive <scp>ALL</scp> with <scp>T315I</scp> mutation or relapsed/refractory disease
Weiyang Liu, Cheng Wang, Wanyan Ouyang, Jie Hao, Jiayi Ren, Lijun Peng, Sijie Tang, Yuanfang Liu, Yongmei Zhu, Xiangqin Weng, Duohui Jing, Sai‐Juan Chen, Jin Wang, Jian‐Qing Mi
Abstract
Third-generation tyrosine kinase inhibitors (TKIs) have much potential for the treatment of BCR::ABL1-positive leukaemia, particularly that harbouring the ABL1 T315I mutation. Olverembatinib (HQP1351), a novel third-generation TKI, has favourable efficacy and safety profiles in chronic myeloid leukaemia. Here, we present the clinical findings from 31 BCR::ABL1-positive acute lymphoblastic leukaemia (ALL) patients who received olverembatinib. Among the 14 patients with overt relapsed/refractory (R/R) disease (including 10 with the T315I mutation), 71.4% achieved an overall response. Of the other 17 patients with minimal residual disease (MRD)-positive ALL (including 14 with the T315I mutation), 60.0% and 47.1% achieved MRD flow negativity and complete molecular remission, respectively. With a median follow-up time of 16.3 months, the median event-free survival and overall survival were 3.9 and 8.3 months respectively, in overt R/R patients, and 11.5 and 18.4 months in MRD-positive patients. Allogeneic haematopoietic stem cell transplantation further improved outcomes among responders. The safety profile was generally manageable. This study suggests that olverembatinib-based therapy is another promising option for BCR::ABL1-positive ALL in addition to ponatinib, especially for patients with MRD-positive disease and a single T315I mutation.